We're picking up more shares of an out-of-favor stock with a bright future

We are buying 50 shares of Johnson & Johnson at roughly $221.43. Following the trade, Jim Cramer's Charitable Trust will own 340 shares of JNJ, increasing its weighting to 1.9% from 1.62%. We're picking up shares of J & J here and lowering our average cost basis as healthcare and drug stocks move lower on Monday. The group came under pressure after oil prices surged and interest rates climbed in response to another potential setback in the U.S.-Iran peace deal negotiations. Healthcare is one of only two sectors in the market down for the year, alongside financials. Johnson & Johnson's stock has dipped about 3% since the beginning of May because healthcare has become completely unfavored in this AI-driven bull market. We'll take advantage of these negative group moves and continue to scale into this position gradually. The pharma and medical technology giant has a strong multiyear growth outlook, driven by the ramp up of several new drugs. The one we are most positive on is Icoytde, the recently approved oral IL-23 inhibitor to treat moderate to severe plaque psoriasis. At the 2026 American Society of Clinical Oncology meeting over the weekend, J & J provided several encouraging updates to its oncology portfolio, including positive data for Rybrevant for advanced head and neck cancer and Erleada in prostate cancer. Analysts at Leerink wrote Monday morning that both drugs could become the standard of care in the populations studied. (Jim Cramer's Charitable Trust is long JNJ. …